erythrocytosis, molecular diagnostics, polycythemia vera, renal cell carcinoma

1. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. Can Med Assoc J. 2020 Aug;192(32):E913–18. http://dx.doi.org/10.1503/cmaj.191587
2. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et  al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019 Jan;184(2):176–91. http://dx.doi.org/10.1111/bjh.15648
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar;365(9464):1054–61. http://dx.doi.org/10.1016/S0140-6736(05)71142-9
4. Jalowiec KA, Vrotniakaite-Bajerciene K, Jalowiec J, Frey N,
Capraru A, Wojtovicova T, et al. JAK2 unmutated polycythaemia – real-world data of 10 years from a tertiary reference hospital. J Clinical Med. 2022 Jun;11(12):3393. http://dx.doi.org/10.3390/ jcm11123393
5. Namdaro-lu S, Tekgündüz E, Altuntaş F. Coexistence of essential thrombocythemia, iron-refractory iron deficiency anaemia and renal cell carcinoma. Hematol Rep. 2016 Mar;8(1):6235. http://dx.doi.org/10.4081/hr.2016.6235
6. Zhao J, Moch H. Absence of JH2 domain mutations of the tyrosine kinase JAK2 in renal cell carcinomas. Acta Oncol. 2008;47(3):474–6. http://dx.doi.org/10.1080/02841860701499390